1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Loibl S, Martin M, Bonnefoi H, Untch M, Kim SB, Bear HD, García-Sáenz JA, Melé Olivé M, Mc Carthy N, Gelmon K, Kelly CM, Im SA, Reimer T, Martinez-Janez M, Zhang Z, Toi M, Provencher L, Rugo HS, Gnant M, Makris A, Antón Torres A, Hirmas N, Holtschmidt J, Nekljudova V, Marmé F.

    Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

    Annals of oncology : official journal of the European Society for Medical Oncology . 36(7): 832-837.

    [doi:10.1016/j.annonc.2025.03.010]

  • Niedra H, Rogoza O, Saksis R, Peculis R, Halilova A, Gerina A, Vilisova S, Senterjakova N, Pukitis A, Ruz-Caracuel I, Earl J, Kolnikova G, Dubovan P, Tomas M, Makovicky P, Urbanova M, Smolkova B, Koniaris E, Aggelioudaki I, Kataki A, Rovite V.

    Transcriptomic profiling of pancreatic neuroendocrine tumors: dysregulation of WNT, MAPK, PI3K, neddylation pathways and potential non-invasive biomarkers.

    Plos One . 20(6): .

    [doi:10.1371/journal.pone.0325672]

  • Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, Cruz P, Maroto P.

    Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.

    CANCER TREATMENT REVIEWS . 136: 102925-102925.

    [doi:10.1016/j.ctrv.2025.102925]

  • Herranz-Montoya I, Angulo-Aguado M, Perna C, Zagorac S, García-Jimeno L, Park S, Djouder N.

    p53 protein degradation redefines the initiation mechanisms and drives transitional mutations in colorectal cancer.

    NATURE COMMUNICATIONS . 16(1): 3934-3934.

    [doi:10.1038/s41467-025-59282-4]

  • Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A.

    A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

    Bmc Cancer . 25(1): 613-613.

    [doi:10.1186/s12885-025-13941-3]

  • Borque-Fernando Á, Alonso-Gordoa T, Juan-Fita MJ, Lopez Campos F, Pérez-Fentes DA, Vilaseca A, Agut CM, Usán P, Rey PM.

    Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.

    FUTURE ONCOLOGY . 21(8): 991-1003.

    [doi:10.1080/14796694.2025.2468569]

  • Fernández-Abad M, Caniego-Casas T, Carretero-Barrio I, Calderay-Domínguez M, Saavedra C, Hardisson D, Palacios J, Pérez-Mies B.

    Ipsilateral Breast Carcinoma Recurrence: True Recurrence or New Primary? A Clinicopathologic and Molecular Study.

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 49(3): 294-302.

    [doi:10.1097/PAS.0000000000002351]

  • Cortés-Salgado A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, Cristóbal E, Del Campo-Albendea L, Guerra E, Alía V, de Aguado PP, Corraliza V, Palacios J, Pérez-Mies B.

    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.

    GYNECOLOGIC ONCOLOGY . 194: 33-40.

    [doi:10.1016/j.ygyno.2025.02.005]

  • Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E.

    Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.

    EUROPEAN JOURNAL OF CANCER . 217: 115219-115219.

    [doi:10.1016/j.ejca.2024.115219]

  • Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Mackowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS.

    Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.

    EUROPEAN JOURNAL OF CANCER . 216: 115146-115146.

    [doi:10.1016/j.ejca.2024.115146]

  • González-Martínez S, Palacios J, Carretero-Barrio I, Lanza VF, García-Cosío Piqueras M, Caniego-Casas T, Hardisson D, Esteban-Rodríguez I, Cortés J, Pérez-Mies B.

    Single-Cell RNA Sequencing on Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Identified Multi-Ciliary Cells in Breast Cancer.

    Cells . 14(3): .

    [doi:10.3390/cells14030197]

  • González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F.

    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

    JOURNAL OF CLINICAL ONCOLOGY . 42(36): 4294-4304.

    [doi:10.1200/JCO.24.00668]

  • Ruz-Caracuel I, Pedraza-Arevalo S, Alonso-Gordoa T, Molina-Cerrillo J, Earl J, Sainz B Jr.

    Everything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask.

    Endocrine Oncology (bristol, England) . 4(1): .

    [doi:10.1530/EO-24-0006]

  • Grazioso TP, Del Mar Rigual M, Perna C, Caleiras EJ, Djouder N.

    Cold exposure reinstates NAD(+) levels and attenuates hepatocellular carcinoma.

    Cell Stress . 8: 125-139.

    [doi:10.15698/cst2024.12.302]

  • Berges-Gimeno MP, Barra-Castro A, Fernandez-Lozano C, Solano-Solares E, Martinez-Jañez N, Pueyo-Lopez C, Martínez-Botas J.

    Two Nonimmediate Reactions to Oxaliplatin and Docetaxel Confirmed by Lymphocyte Transformation Test and Treated With Successful Rapid Desensitization Procedures.

    Journal of investigational allergology & clinical immunology . : 0-0.

    [doi:10.18176/jiaci.1030]

  • Bonura GF, Biancheri P, Rainer J, Soriani P, Rodriguez de Santiago E, Parrella A, Campioli A, Guerra E, Gualdi E, Pignatti A, Manno M.

    Spinal anesthesia for endoscopic submucosal dissection of large rectosigmoid lesions: Feasibility study.

    Endoscopy International Open . 12(12): 1447-1452.

    [doi:10.1055/a-2441-2543]

  • Montégut C, Falandry C, Cinieri S, Cropet C, Montane L, Rousseau F, Joly F, Moubarak M, Mosconi AM, Guerra-Alía EM, Schauer C, Fujiwara H, Vergote I, Parma G, Lindahl G, Anota A, Canzler U, Marmé F, Pujade-Lauraine E, Ray-Coquard I, Sabatier R.

    Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA-1/ENGOT-ov25.

    ONCOLOGIST . : .

    [doi:10.1093/oncolo/oyae322]

  • Mata-Castro N, Castañeda-Vozmediano R, Perna C, Prada Puentes C, Sanz López L.

    Histological Findings of Resected Tracheal Ring in SARS-CoV-2-Positive and -Negative Tracheostomized Patients.

    LIFE-BASEL . 14(12): .

    [doi:10.3390/life14121655]